Alexandria Real Estate (ARE): The Bull Case — Why the Worst May Already Be Priced In

The Contrarian Setup

Let me lay out the bear case for Alexandria Real Estate first, because it’s important to acknowledge what everyone already knows. The stock has been cut in half — down roughly 52% from its 52-week high of $101 in March 2025 to around $48 today. Market cap has shrunk from about $17.5 billion to $8.4 billion in under a year. Management cut the dividend by 45% — the first cut since the 2009 financial crisis — taking the quarterly payout from $1.32 to $0.72 per share. They took $2.2 billion in impairment charges in 2025 alone. Occupancy slid from 94.6% to 90.9%. The NIH is under political siege (though courts have blocked the proposed 15% indirect cost rate cap). The IPO window is essentially closed — just 8 biotech IPOs in 2025 versus 100 in 2021. We’re in what management itself calls the fifth consecutive year of a broad-based biotech bear market.

That’s the bear case, and it’s real. But here’s the thing: every single one of those facts is already priced into a stock trading at $48. ARE isn’t even alone in cutting its dividend — Boston Properties (BXP) also cut theirs by 29% in Q3 2025. The entire sector is repricing. The question isn’t whether things have been bad — they have. The question is whether the current price already reflects that reality, and whether any incremental improvement from here gets rewarded.

What makes this setup interesting is that ARE’s own peers — the companies competing for the same tenants in the same markets — are starting to signal that the bottom is forming. One of them is backing that conviction with capital. From a base of maximum pessimism, even minor positive catalysts can drive meaningful re-rating.

The Peers See a Bottom Forming

Healthpeak Properties (DOC) — Buying Into the Distress

DOC is ARE’s closest public comp in life science real estate, and their recent commentary has been the most bullish we’ve heard from any life science landlord in two years. More importantly, they’re backing it with capital.

On the Q3 2025 earnings call, CEO Scott Brinker didn’t mince words:

The past 60 days or so signal a turning point in our business. Leading indicators in life science are turning positive.

(Source: DOC Q3 2025 Earnings Call, Scott Brinker)

Brinker backed it up with specifics. DOC’s leasing pipeline had roughly doubled since the start of the year. CFO Kelvin Moses added: “Since Q1, the pipeline has doubled to 1.8 million square feet, about half are evaluating our current unleased availabilities. Each of our core markets is experiencing a similar uptick in demand.” Moses expressed growing confidence: “We’re now gaining more confidence that will be the bottom of occupancy.” (Source: DOC Q3 2025 Earnings Call, Kelvin Moses)

But Moses was also candid about the near-term path: “Occupancy could trend down somewhere in the high 70s before it starts to pick back up again.” DOC’s lab portfolio ended Q3 at 77% occupancy — significantly below ARE’s 90.9%, underscoring the gap between ARE’s Megacampus-concentrated portfolio and DOC’s more diversified healthcare platform. (Source: DOC Q3 2025 Earnings Call, Kelvin Moses)

By Q4 2025, Brinker went further: “New deliveries will soon go to zero and will remain at zero for several years. Certain life science buildings are pivoting to alternative uses, which helps address the supply overhang. All of the above points to early signs of an inflection point.” (Source: DOC Q4 2025 Earnings Call, Scott Brinker)

But the most telling signal was DOC’s actions, not just words. In late December 2025, Healthpeak acquired a 1.4 million square foot campus in South San Francisco — with over 500,000 SF of vacancy — recycling proceeds from stabilized outpatient medical asset sales at a low 6% cap rate. DOC now controls roughly one-third of all land in the entire South San Francisco submarket. They’re targeting “certainly double-digit unlevered IRRs” on distressed life science acquisitions. (Source: DOC Q4 2025 Earnings Call, Scott Brinker)

Brinker framed the opportunity perfectly: “We see a window here to come in at a time when nobody else wants to invest. That’s usually a pretty good time to do it.” (Source: DOC Q4 2025 Earnings Call, Scott Brinker)

Entering 2026, DOC’s pipeline was 50% higher than a year earlier, weighted more toward new leasing. Brinker expects total occupancy to improve by year-end 2026. Their watch list has “reduced considerably as tenants have raised capital.” (Source: DOC Q4 2025 Earnings Call, Kelvin Moses)

On timing, Brinker estimated 12 to 24 months for the sector to find a genuine bottom — with a quote that matters most for ARE investors:

I expect the core submarkets to recover first, and I anticipate that the major incumbent landlords, of which there are only a few, will recover more quickly.

(Source: DOC Q4 2025 Earnings Call, Scott Brinker)

ARE captured 94% of combined leasing volume among the five largest life science real estate owners from 2023 to 2025. When Brinker says incumbent landlords will recover first, he’s describing ARE.

Boston Properties (BXP) — Cautious but Confirming the Trend

BXP isn’t a life science REIT, but they operate significant lab-adjacent space in Boston and the Bay Area. Their Q3 2025 commentary provided a useful reality check from the office side of the equation.

President Douglas Linde was blunt about current conditions: “Demand for wet lab space continues to be tepid.” But he qualified this with an important distinction — demand for office space leased to life science tenants has been robust, with BXP completing several deals for pharma and biotech companies in traditional office product. (Source: BXP Q3 2025 Earnings Call, Douglas Linde)

This confirms something ARE’s leasing data already suggests: life science tenants are active, but many are opting for flex or office-adjacent space rather than purpose-built wet lab. The tenants haven’t disappeared — they’re just making different space decisions during the downturn.

Kilroy Realty (KRC)

Kilroy isn’t a pure-play life science REIT, but their Q3 2025 results showed similar signals. CEO Angela Aman highlighted “momentum building across every component of our business, with strong new leasing activity across both the stabilized and development portfolios.” KRC signed 84,000 SF of life science leases at Oyster Point Phase 2, including MBC BioLabs — the Bay Area’s leading life science incubator. (Source: KRC Q3 2025 8-K, Angela Aman)

ARE’s Own Q4 2025 Signals

ARE’s Q4 2025 delivered the strongest leasing quarter since the downturn began. Q4 leasing volume hit 1.2 million square feet — up 14% over the prior four-quarter average. Vacant space leasing hit 393,000 SF, up 98% over the five-quarter average. (Source: ARE 2025 10-K)

On the Q3 2025 earnings call, COO Peter Moglia noted encouraging demand signals in ARE’s most challenged market: “Greater Boston region did see an 11% increase in tenants in the market.” (Source: ARE Q3 2025 Earnings Call, Peter Moglia) By Q4, EVP of Leasing Hallie Kuhn described demand as “pretty diverse from a regional perspective,” suggesting the recovery is broadening beyond any single geography. (Source: ARE Q4 2025 Earnings Call, Hallie Kuhn)

The reported occupancy figure requires honest context. Headline occupancy ticked up 30 basis points to 90.9%, but the 10-K’s own bridge reveals the mechanics:

Without removing low-occupancy properties via held-for-sale reclassification, occupancy would have declined about 20 bps. Management plans to repeat this at double the scale in 2026, guiding for a 2% HFS benefit.

But the +0.6% from actual lease commencements is real demand. The 393K SF of vacant space leasing is real. And ARE has 900,000 SF of signed leases commencing around Q3 2026, generating $52 million in incremental annual revenue. Full-year 2025 leasing totaled 4.2 million RSF with an 11.9-year weighted-average lease term. In July 2025, ARE signed the largest life science lease in company history: a 16-year, 466,598 RSF build-to-suit at Campus Point in San Diego.

Full-Year 2025 Life Science Leasing — ARE vs. Peers

Comparing full-year 2025 leasing volumes across the major life science landlords puts ARE’s dominance in perspective. No other company comes close in scale, lease duration, or market coverage.

ARE leased nearly 3x more than DOC and roughly 50x more than KRC in 2025. DOC’s 562,000 SF of new leasing in Q4 was a record quarter for their lab platform — and it was still half of ARE’s 1.2 million SF total Q4 volume. The scale differential is extraordinary and reflects ARE’s structural advantage in Megacampus properties.

Supply Is Collapsing — And That Changes Everything

The supply side of the equation is arguably the most compelling part of the bull case — and it’s the one getting the least attention. New life science construction has collapsed, and multiple sources confirm it will stay at zero for years.

DOC’s November 2024 investor presentation laid out the data starkly:

DOC’s Brinker confirmed in Q1 2025: “We have even more confidence today that new supply in the sector will essentially go to zero for many years to come. This is obviously a great foundation for recovery in our lab business.” DOC hasn’t started a new development since 2021. (Source: DOC Q1 2025 Earnings Call, Scott Brinker)

BXP’s Douglas Linde confirmed the trend from the office side as early as Q3 2023: “New speculative construction is non-existent.” Two years later, the pipeline is still empty — zero new speculative lab starts in any major market. (Source: BXP Q3 2023 Earnings Call, Douglas Linde)

ARE’s Peter Moglia echoed the trend market by market: San Francisco expects “no additional supply to be delivered after this year.” San Diego’s 2026 deliveries are 100% pre-leased. On the Q4 2025 earnings call, Moglia estimated “2 to 3 years for that situation to rectify” in core submarkets — meaning the window for incumbents to lock in tenants before the market rebalances may be narrower than bears expect. (Source: ARE Q4 2025 Earnings Call, Peter Moglia)

And even the elevated availability isn’t what it seems — ARE cited JLL data identifying a significant portion of the ~29% aggregate availability in its top markets as “zombie buildings”: poorly conceived office-to-lab conversions by inexperienced developers that are “likely un-leasable as laboratory space.” (Source: ARE Q1 2025 Earnings Call, Peter Moglia)

Market Availability Rates — ARE’s Top 3 Markets

The 29% headline availability includes zombie buildings, sublease space, and properties being converted to alternative uses. ARE’s vacancy rate of ~9% is less than one-third the ~29% market availability — reflecting the quality premium that Megacampus properties command.

Meanwhile, supply is being actively removed through conversions. ARE reports that 55% of its available land can be used for residential, and residential developers were one of their largest buyer segments in 2025. In Mission Bay, ARE obtained Prop M office allocations to serve AI companies including OpenAI. BXP pivoted a planned lab repositioning at 1050 Winter Street back to office for a defense contractor because “the economics of doing an office transaction on raw space… are far superior to a lab transaction.” (Source: BXP Q1 2025 Earnings Call, Douglas Linde)

The math is straightforward: when supply goes to zero and demand even modestly inflects upward, the market rebalances. ARE’s Moglia estimates 2–3 years in core submarkets, possibly faster if alternative-use conversions accelerate.

Understanding the FFO Drop — From $9.01 to $6.40

Before talking about dividend safety, it’s important to understand why FFO is declining 29% from $9.01 in 2025 to a guided midpoint of $6.40 in 2026. ARE’s December 2025 Investor Day provided an explicit bridge:

The 2026 guidance range is $6.25 to $6.55. Same-property NOI is guided to decline 8.5% — the worst in company history. Key lease expirations totaling 1.2 million RSF with $71 million in annual rental revenue roll off with 6–24 months of expected downtime. This is the pain already priced into the stock.

Where does FFO bottom? Management guided Q4 2026 FFO at $1.40 to $1.60 per share — the trough quarter. Joel Marcus called this “a good run rate to think about as a base” for 2027. If occupancy stabilizes and the disposition program winds down, the path back toward $7+ FFO becomes visible. That’s the recovery not priced in.

The Dividend Is Safe

The 45% dividend cut was painful. But now that it’s done, the new dividend is well-covered — and ARE’s payout ratio is the most conservative among its peers.

The contrast is instructive. DOC raised its dividend — CEO Scott Brinker announced on the Q4 2025 call: “Yesterday we announced an increase to our dividend.” BXP cut deeper as a percentage of FAD, with CFO Michael LaBelle citing the need to retain capital for upcoming debt maturities. ARE chose the most aggressive cut to create maximum financial flexibility — and the result is the lowest payout ratio in the peer group by a wide margin. (Source: DOC Q4 2025 Earnings Call, Scott Brinker)

Even at the low end of 2026 FFO guidance ($6.25), the payout ratio is only 46% — well below the typical 70–80% REIT range. Management explicitly guides $475–575 million of net cash from operations after dividends for 2026 (midpoint $525M). The cut freed up roughly $410 million in annual capital.

At the current stock price of ~$48, the new dividend yields approximately 6.0% — a meaningful income return with significant room for growth once the cycle turns. ARE’s REIT taxable income further constrains the possibility of another cut. On the Q3 2025 call, CFO Marc Binda noted that taxable income could rise 30–40% due to disposition gains, which would actually increase the minimum required distribution — making a further dividend reduction virtually impossible.

Balance Sheet Is a Fortress — And It’s a Peer Outlier

ARE’s balance sheet isn’t just strong in isolation — it’s dramatically superior to peers on the metrics that matter most in a rising-rate environment.

ARE’s weighted-average debt maturity is nearly 3x longer than both DOC and BXP — the longest among all S&P 500 REITs. This matters enormously right now. DOC’s CFO Kelvin Moses explicitly cited refinancing at higher rates as a 2026 FFO headwind: “Refinancing borrowing costs are just higher today… another reduction to our 2026 FFO.” (Source: DOC Q4 2025 Earnings Call, Kelvin Moses)

DOC needs to refinance $1.1 billion in 2026 including $650 million of senior notes and $440 million of mortgages. Even at favorable terms — DOC priced $500 million of senior unsecured notes at 4.75% in Q3 2025, which Moses called “one of the tightest investment-grade REIT 7-year spreads” — the incremental cost is material. ARE faces no such pressure — only 11% of its total debt matures through 2028. (Source: DOC Q3 2025 Earnings Call, Kelvin Moses)

The embedded value of those below-market fixed-rate bonds — roughly $8 per share per the Investors Day presentation — represents nearly 17% of the current market cap. That’s hidden equity.

The Q1 2026 Debt Tender

In February 2026, ARE issued $750 million of new 5.25% Senior Notes due 2036, then launched a cash tender for lower-coupon notes trading at discounts to par. They purchased tendered notes for ~$952 million — and with 2–3% coupon bonds trading at 15–40% discounts, ARE will likely recognize a gain on early extinguishment of debt in Q1 2026. Combined with $642 million in gains on real estate sales in 2025 and the $300 million of 4.30% notes repaid at maturity in January, ARE is systematically delevering from a position of strength.

Which Properties Get Sold Next — and What Impairments to Expect

ARE’s 2025 impairments were front-loaded — the biggest write-downs are done. But the 10-K explicitly warns: “We may incur material real estate impairments in 2026.” Understanding where the remaining risk lies requires a property-level analysis of what’s already been impaired, what’s likely to be designated held for sale next, and what the incremental charges could be. (Source: ARE 2025 10-K)

2025 Impairments — The Biggest Write-Downs Are Done

These impairments represented a one-time portfolio re-pricing — 10x the prior year’s charges. The properties driving the largest write-downs (SoMa, Gateway, Cambridge, Seaport, ACLS) have already been marked to fair value and are either held for sale or will be disposed of at current carrying values.

Properties Already Held for Sale — No New Charges Expected

ARE currently has 20 properties designated held for sale. These have already been impaired to estimated fair value, meaning no significant additional charges are expected upon closing.

Next Wave — Properties Likely to Be Designated Held for Sale in 2026

ARE’s $2.9 billion disposition target implies significant additional sales beyond what’s currently held for sale. The following categories are the most likely candidates for new held-for-sale designations — and new impairments.

Life Science Cap Rate Trajectory

Cap rates have roughly doubled from their 2021 lows for non-core assets, meaning prices have fallen 30–50%. For core Megacampus assets, cap rates have widened more modestly — ARE’s COO Peter Moglia noted “five-handle” cap rates on core campus assets, implying far less impairment risk on the best properties. (Source: ARE Q2 2025 Earnings Call, Peter Moglia)

Why $300–500M and Not $2.2B Again

I estimate 2026 impairments of $300–500 million — material, but a fraction of 2025’s charges. Here’s why:

1. The biggest write-downs are done. The five largest 2025 impairments (SoMa $478M, Gateway $385M, Cambridge $262M, Seaport $236M, ACLS $206M) totaled $1.57 billion — 71% of the total. These assets are either held for sale at fair value or already disposed.

2. Held-for-sale properties are already at fair value. The $582M in current held-for-sale book value reflects $911M in cumulative impairments already taken. Closing these sales generates no new charges.

3. 25–35% of dispositions are core assets selling near book. One or two JV transactions on Megacampus properties at 5-handle cap rates should transact near or above carrying value.

4. 2025 was a one-time portfolio re-pricing. The 10x year-over-year increase in impairments reflected management’s strategic pivot — exiting non-core markets (Montreal, NYC, RTP) and marking challenged development projects to reality. That re-pricing is largely complete.

5. But management warns of “material” impairments. The 10-K’s language is deliberate. Non-Megacampus operating assets in Boston and SF, development projects with 8% leasing, and land parcels all carry impairment risk. $200–300M would be too optimistic given these exposures.

The buyer pool has diversified: residential developers, municipalities, healthcare systems, PE firms, and universities. This isn’t fire-sale territory — it’s an orderly disposition of non-strategic assets from a position of strength, with the largest write-downs already behind us.

Megacampus Outperformance — The Moat Is Working

San Diego is the showcase: 97.2% occupancy overall, with Campus Point at 99.5%. Other markets are more challenged — Greater Boston at 86.4%, Seattle at 88.4% — but even within those markets, Megacampus properties consistently outperform their non-cluster counterparts.

Megacampus properties generate 78% of ARE’s annual rental revenue, approaching 80%. As dispositions shed non-core assets, this concentration will increase — the go-forward portfolio will be higher-quality than the one the market is discounting. From 2023 to 2025, ARE captured 94% of combined leasing volume among the five largest life science real estate owners — leasing 105% of the next five largest competitors combined.

What Needs to Go Right

The bull case doesn’t require everything to go perfectly. It requires some of the following — and the base rate for cyclical normalization is reasonably high.

The IPO Window and VC Capital

Biotech capital markets are at their most depressed since 2008–2009:

ARE’s Hallie Kuhn said the IPO window opening is “really top of mind as we think about the next 12 to 18 months.” Even a normalization to 2019 levels (47 IPOs, $5.3B) would be a significant catalyst.

NIH Funding — Sentiment Worse Than Reality

The 15% indirect cost cap was blocked by federal courts — permanent injunction April 2025, affirmed by the First Circuit in January 2026. The NIH budget remains at ~$48 billion under a continuing resolution; the proposed 40% cut has not been enacted. During Trump’s first term, NIH cuts were proposed every year but Congress passed increases each time.

Bio-Techne’s CFO Jim Hippel captured the bull case perfectly: “What we’re experiencing now in academic, from a behavior perspective, might be worse than any actual negative outcome of the funding. I actually view a resolution… whether that’s flat, minus 10% or even minus 15%… as upside, because we believe customers are actually behaving more conservative than even the worst-case scenario.”

Charles River Labs reported only ~$3M in actual annual revenue loss from NIH disruption — and CEO James Foster was explicit that the broader impact has been manageable: “Effects of government funding reductions, including at the NIH, have been minimal.” ARE itself has minimal direct NIH tenant exposure — Joel Marcus: “a few leases” in the Maryland market. Any resolution of the uncertainty is itself a positive catalyst. (Source: CRL Q2 2025 Earnings Call, James Foster)

FDA Stabilization

Despite 50%+ senior FDA leadership departing in the first half of 2025 and deadlines delayed at triple the normal rate in Q3, the FDA approved 52 drugs in 2025 — right in line with the ten-year average. (Source: ARE December 2025 Investor Day)

DOC’s Brinker polled 30 biopharma CEOs at the JPMorgan Healthcare Conference in January 2026: “The response was that the feedback they’re receiving from the agency is normal and responsive.” (Source: DOC Q4 2025 Earnings Call, Scott Brinker)

The FDA Commissioner is exploring process improvements including conditional approvals that could shorten costly Phase 3 trials. DOC’s Q3 2025 call cited “10 tenants in the portfolio that have received various forms of fast track or regulatory priority reviews” from the current administration. (Source: DOC Q3 2025 Earnings Call, Scott Brinker) The worst fears of a dysfunctional FDA have not materialized.

Pharma M&A and the Patent Cliff

The patent cliff — $200+ billion in pharma revenues coming off patent by 2030 — is forcing record M&A activity. First-half 2025 M&A already exceeded all of 2024. ARE’s Hallie Kuhn reported $113 billion in biopharma licensing deals in H1 2025 alone. (Source: ARE Q2 2025 Earnings Call, Hallie Kuhn)

DOC’s Brinker confirmed the acceleration: “M&A year-to-date is something like 3x 2024.” ARE’s Investor Day presentation quantified why this matters for lab demand: “64% of revenue is driven by external partnerships and M&A” — meaning every dollar of biopharma M&A spending directly generates lab space requirements for the combined entity. (Source: DOC Q3 2025 Earnings Call, Scott Brinker)

Charles River Labs’ CEO said pharma has “strengthened meaningfully” by Q2 2025 as the worst cost-cutting in anticipation of the patent cliff “has happened.” (Source: CRL Q3 2025 Earnings Call, James Foster)

The IRA drug pricing headwind is fading. Danaher’s CEO Rainer Blair noted “more confidence now in making investment decisions as some of these most favored nation negotiations are becoming workable solutions” and that “pharma has shown growth here for three quarters in a row.” DOC’s Brinker flagged that the IRA’s “pill penalty” may be eliminated, extending small molecule exclusivity by four years. (Source: DHR Q4 2025 Earnings Call, Rainer Blair)

China Competition and the Reshoring Tailwind

Drug development in China takes one-third the time and costs 50–90% less than in the West. (Source: ARE Q3 2025 Earnings Call, Joel Marcus) But the policy response is creating a long-term tailwind for U.S. lab demand. DOC’s Brinker stated: “Policymakers in a bipartisan way have correctly identified U.S.-based biopharma as being paramount to our national security… The push to onshore biomanufacturing would logically include R&D as well.” (Source: DOC Q1 2025 Earnings Call, Scott Brinker)

Charles River Labs reported that major VC firms have “instructed their portfolio companies to refrain from working in China… They didn’t just suggest preference; they outright stated their disapproval.” (Source: CRL Q2 2024 Earnings Call, James Foster) Danaher’s CEO called this “the early innings of a long-term investment cycle.” (Source: DHR Q4 2025 Earnings Call, Rainer Blair) The timeline is 3–5+ years for meaningful impact, but the direction is clear.

Asymmetric Risk/Reward

The downside scenario — occupancy slides further, NIH funding gets gutted, dispositions at fire-sale prices — is largely reflected in a stock cut in half. At $48 and $8.4 billion, ARE trades at levels not seen since before the pandemic. Maybe another 15–20% in a severe scenario. But the probability diminishes every quarter.

The upside scenario — occupancy stabilizes, the sector recovery DOC is calling for materializes in late 2026, dispositions execute cleanly, management signals a path back to dividend growth — could drive 40–60% from here. Not because anything spectacular must happen, but because the removal of negatives is itself a positive from a deeply discounted base.

Healthpeak — ARE’s closest comp — is buying distressed life science assets at prices that imply double-digit returns. New supply is going to zero for years. The FDA is still approving drugs. Pharma M&A is at record levels. VC firms are directing portfolio companies away from China and toward U.S. labs. And ARE is the dominant franchise, capturing 94% of life science leasing among major landlords.

At the current price, you’re buying that franchise at a cycle-low valuation, with a well-covered 6.0% yield, a fortress balance sheet with 12.1 years of debt maturity at 3.9%, $5.3 billion in liquidity, and a management team that has navigated ARE through the GFC and the dot-com bust. The stock price says maximum pessimism. The leasing data and peer commentary say the worst may be behind us. That’s exactly the kind of disconnect where long-term returns are made.